Regulating fatty acids in infant formula: critical assessment of U.S. policies and practices

International Breastfeeding Journal

George Kent¹ 

[1] Department of Political Science, University of Hawai’i, Honolulu, HI 96822, USA

关键词: DHA;    Docosahexaenoic acid;    Regulation;    Fatty acids;    Infant formula;   

Others  :  800877
DOI  :  10.1186/1746-4358-9-2

 received in 2012-12-04, accepted in 2013-09-01,  发布年份 2014

【 摘 要 】

Background

Fatty acids in breast-milk such as docosahexaenoic acid and arachidonic acid, commonly known as DHA and ARA, contribute to the healthy development of children in various ways. However, the manufactured versions that are added to infant formula might not have the same health benefits as those in breast-milk. There is evidence that the manufactured additives might cause harm to infants’ health, and they might lead to unwarranted increases in the cost of infant formula.

The addition of such fatty acids to infant formula needs to be regulated. In the U.S., the Food and Drug Administration has primary responsibility for regulating the composition of infant formula. The central purpose of this study is to assess the FDA’s efforts with regard to the regulation of fatty acids in infant formula.

Methods

This study is based on critical analysis of policies and practices described in publicly available documents of the FDA, the manufacturers of fatty acids, and other relevant organizations. The broad framework for this work was set out by the author in his book on Regulating Infant Formula, published in 2011.

Results

The FDA does not assess the safety or the health impacts of fatty acid additives to infant formula before they are marketed, and there is no systematic assessment after marketing is underway. Rather than making its own independent assessments, the FDA accepts the manufacturers’ claims regarding their products’ safety and effectiveness.

Conclusions

The FDA is not adequately regulating the use of fatty acid additives to infant formula. This results in exposure of infants to potential risks. Adverse reactions are already on record. Also, the additives have led to increasing costs of infant formula despite the lack of proven benefits to normal, full term infants. There is a need for more effective regulation of DHA and ARA additives to infant formula.

【 授权许可】

   
2014 Kent; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Brody JE: Experts disagree on adding fatty acid to infant formula. New York Times 1996. [http://www.nytimes.com/1996/11/06/us/experts-disagree-on-adding-fatty-acid-to-infant-formula.html?pagewanted=all&src=pm webcite]
• [2]Guidice C: Harmonisation: Mercosur gets to work on nutrition claims. EAS Strateg Advice: Europe 2012. [http://www.eas.eu/News_Item/921 webcite]
• [3]Astley M: ISO to cooperate with AOAC on infant formula standards. Nutra Ingredients.com 2012. [http://www.nutraingredients.com/Regulation/ISO-to-cooperate-with-AOAC-on-infant-formula-standards webcite]
• [4]GOED: Global Organization for EPA and DHA Omega-3. 2012. Website [http://www.goedomega3.com webcite]
• [5]Codex Alimentarius Commission: Standard for Infant Formula and Formulas for Special Medical Purposes Intended for Infants. CODEX STAN 72–1981. (Formerly CAC/RS 72–1972. Adopted as a world-wide Standard 1981. Amended 1983, 1985, 1987. Revision 2007. Amended 2011). [http://www.codexalimentarius.org webcite]
• [6]U.S. Code of Federal Regulations: Title 21 Part 107 (21CFR107). 2003. [http://www.access.gpo.gov/nara/cfr/waisidx_03/21cfr107_03.html webcite]
• [7]Gibson RA, Barclay D, Marshall H, Moulin J, Maire J-C, Makrides M: Safety of supplementing infant formula with long-chain polyunsaturated fatty acids and Bifidobacterium lactis in term infants: a randomized controlled trial. Br J Nutr 2009, 101(11):1706-1713.
• [8]Kent G: Regulating infant formula. Amarillo, Texas: Hale Publishing; 2011.
• [9]U.S. Department of Health and Human Services: Beech-Nut Corporation 2/22/10. Warning Letter. Washington, DC: USDHHS: Food and Drug Administration; 2010. [http://www.fda.gov/iceci/enforcementactions/warningletters/ucm202834.htm webcite]
• [10]Vallaeys C: Replacing mother–imitating human breast milk in the laboratory. Cornucopia, Wisconsin: Cornucopia Institute; 2008. [http://www.cornucopia.org/2008/01/replacing-mother-infant-formula-report/ webcite
• [11]Living Wholesome: Horizon organic gets flogged for bending its definition of ‘organic’. Living Wholesome 2011.
• [12]Mitchell C: Challenge to horizon organic’s DHA fortified milk. Food Safety News 2011. [http://www.foodsafetynews.com/2011/03/challenge-to-horizon-organics-new-dha-fortified-milk/ webcite]
• [13]U.S. Department of Health and Human Services: Letter to Deputy Administrator of National Organic Program, USDA. Washington, DC: USDHHS: Food and Drug Administration; 2011.
• [14]Mullaney TJ: Martek sells its first product. Baltimore Sun 1994. [http://articles.baltimoresun.com/1994-12-14/business/1994348144_1_martek-biotechnology-baby-formulas webcite]
• [15]Martek: Infant benefits: DHA & ARA for infants health. Life’s DHA: Healthy Brain, Eyes, Heart 2012. [http://www.lifesdha.com/dha-at-every-age/infants.aspx webcite]
• [16]Qawasmi A, Landeros-Weisenberger A, Leckman JF, Bloch MH: Meta-analysis of long-chain polyunsaturated fatty acid supplementation of formula and infant cognition. Pediatrics 2012., 129(6)
• [17]Simmer K, Schulzke S, Patole S: Longchain polyunsaturated fatty acid supplementation in preterm infants. Cochrane Database Syst Rev 2008.
• [18]Simmer K, Patole S, Rao SC: Longchain polyunsaturated fatty acid supplementation in infants born at term. Cochrane Database Syst Rev 2008.
• [19]Martek: Infant development: the benefits of DHA and ARA during infancy. 2012. [http://www.lifesdha.com/clinical-research/infant-development.aspx webcite]
• [20]Martek: Martek to be the sole-source supplier of DHA and ARA for prodigy brand infant formula products in China. Columbia, Maryland: Martek Biosciences Corporation; 2009. [http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aazU8t4zmy_M webcite]
• [21]Martek: Martek to be the sole source supplier of DHA and ARA for infant formulas produced by Grupo Ricap. Columbia, Maryland: Martek Biosciences Corporation; 2009. [http://www.bloomberg.com/apps/news?pid=newsarchive&sid=a1SoDaBD_5t8 webcite]
• [22]Martek: Martek signs sole-source supply agreement with Fonterra. Columbia, Maryland: Martek Biosciences Corporation; 2009. [http://www.prweb.com/releases/dairy_fonterra/martek_biosciences/prweb3321614.htm webcite]
• [23]Martek: About life’s DHA. 2012. [http://www.lifesdha.com/dha-at-every-age/infants.aspx webcite]
• [24]Colombo J, Carlson SE: Is the measure the message: the BSID and nutritional interventions. Pediatrics 2012, 129(6):1166-1167.
• [25]U.S. Department of Health and Human Services: Questions & answers for consumers concerning infant formula. Washington, DC: USDHHS Food and Drug Administration; 2013. http://www.fda.gov/Food/FoodborneIllnessContaminants/PeopleAtRisk/ucm108079.htm#16 webcite
• [26]Kent G: The nutritional adequacy of infant formula. Clin Lactation 2012, 3(1):21-25.
• [27]Nature’s One: Baby’s Only Essentials® DHA Fatty Acid Supplement. 2012. [http://www.naturesone.com/dha/# webcite]
• [28]Rowlands JC, Hoadley J: FDA perspective on health claims for food labels. Toxicology 2006, 221:35-43.
• [29]Schneeman B: FDA’s review of scientific evidence for health claims. J Nutr 2007, 137(2):493-494.
• [30]Reuterswärd AL: The new EC regulation on nutrition and health claims on foods. Scand J Food Nutr 2007, 51(3):100-106.
• [31]U.S. Department of Health and Human Services: Is it really FDA approved? USDHHS. Food and Drug Administration; 2012. [http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm047470.htm#formula webcite]
• [32]Chung CS, Yamini S, Trumbo PR: FDA’s health claim review: whey-protein partially hydrolyzed infant formula and atopic dermatitis. Pediatrics 2012, 130:2.
• [33]U.S. Department of Health and Human Services: Health claims meeting Significant Scientific Agreement (SSA). USDHHS. Food and Drug Administration; 2012. [http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm2006876.htm webcite]
• [34]Infant Formula Council: Infant Formula Council (IFC) statement on DHA/ARA and infant formula. Infant Feeding & Nutrition 2010. [http://www.infantformula.org/news-room/press-releases-and-statements/infant-formula-and-dha/ara webcite]
• [35]U.S. Department of Health and Human Services: Guidelines concerning notification and testing of infant formulas. Washington, DC: USDHHS, Food and Drug Administration, Center for Food Safety and Applied Nutrition; 2009. [http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/InfantFormula/ucm169730.htm webcite]
• [36]U.S. Department of Health and Human Services: Agency Response Letter, GRAS Notice No. GRN 000041. Washington, DC: USDHHS, Food and Drug Administration; 2001. [http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/ucm154126.htm webcite]
• [37]U.S. Department of Health and Human Services: GRAS notice inventory. USDHHS. Food and Drug Administration; 2012. http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/default.htm webcite
• [38]U.S. Department of Health and Human Services: Guidance for industry: frequently asked questions about GRAS. USDHHS. Food and Drug Administration; 2004. [http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm061846.htm webcite]
• [39]U.S. Department of Health and Human Services: Agency Response Letter, GRAS Notice No. GRN 000080. Washington, DC: USDHHS. Food and Drug Administration; 2001. [http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/ucm154201.htm webcite]
• [40]Vallaeys C: DHA and ARA in infant formula: dangerous and unnecessary—synthetic additives have no place in infant foods. Cornucopia, Wisconsin: Cornucopia Institute; 2012. [http://cornucopia.org/DHA/DHA-Update-2010.pdf webcite]
• [41]Cornucopia: Safety concerns: inadequate safety testing of Martek’s DHA and ARA. Cornucopia, Wisconsin: Cornucopia Institute; 2012. [http://www.cornucopia.org/dha-safety-concerns/ webcite]
• [42]Cornucopia: Official adverse reaction reports filed with the Food and Drug Administration. Cornucopia, Wisconsin: Cornucopia Institute; 2012. [http://cornucopia.org/DHA/AdverseReactionReports.pdf webcite]
• [43]INFACT Canada: Fools gold: recommendation: strong buy. INFACT Canada: Spring 1997 Newsletter: Breastfeeding Protection: Code Watch 1997. [http://www.infactcanada.ca/codewach.htm webcite]
• [44]Neuberger Z: WIC food package should be based on science: foods with new functional ingredients should be provided only if they deliver health or nutritional benefits. Washington, DC: Center on Budget and Policy Priorities; 2010. [http://www.cbpp.org/files/6-4-10fa.pdf webcite]
• [45]Neuberger Z: Podcast: new ingredients raising costs for “WIC” program. Washington, DC: Center on Budget and Policy Priorities; 2010. [http://www.cbpp.org/cms/index.cfm?fa=view&id=3213 webcite]
• [46]Minchin MK: Milk Matters: Immune Disorder and Infant Feeding. Alma Publications 2014. in press
• [47]U.S. Federal Trade Commission: FTC warns marketers of children’s omega-3 fatty acid supplements that claims about brain and vision benefits may be deceptive. Washington, DC: USFTC; 2010. [http://www.ftc.gov/opa/2010/02/omega.shtm webcite]
• [48]U.S. Federal Trade Commission: FTC approves final order settling charges that marketer of children’s vitamins made deceptive claims about DHA and brain and eye development. Washington, DC: USFTC; 2011. [http://www.ftc.gov/opa/2011/03/nbty.shtm webcite]
• [49]U.S. Department of Health and Human Services: Draft guidance for industry: frequently asked questions about medical foods. USDHHS. Food and Drug Administration; 2011. [http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/MedicalFoods/ucm054048.htm#q1 webcite]
• [50]Collier R: Squabble over risks of probiotics infant formula. Can Med Assoc J 2011, 181(3–4):E46-E47.
• [51]Mugambi M, Musekiwa A, Lombard M, Young T, Blaauw R: Probiotics, prebiotics infant formula use in preterm or low birth weight infants: a systematic review. Nutr J 2012., 11(58)
• [52]Probiotic: Safety of probiotic products. Probiotic.org 2011. [http://www.probiotic.org/safety-of-probiotics.htm webcite]
• [53]Shafai T: Routine supplement of prebiotics and probiotics to newborn infants are not recommended [Letter]. Pediatrics 2009, 123:e543-e544.
• [54]Yu VY: Scientific rationale and benefits of nucleotide supplementation of infant formula. J Paediatr Child Health 2002, 38(6):543-549.
• [55]Parker L, Green R: Why doesn’t baby formula list sugar content? Target 5 2012. [http://www.nbcchicago.com/investigations/series/target-5/target-5-sugar-baby-formula-139339308.html webcite]
• [56]UBIC: Ingredients for the world infant formula market. UBIC Consulting 2013. [http://www.ubic-consulting.com/template/fs/documents/Nutraceuticals/Ingredients-in-the-world-infant-formula-market.pdf webcite]
• [57]Renub Research: China baby food & drink market analysis and forecast to 2015. 2012. [http://www.marketresearch.com/Renub-Research-v3619/China-Baby-Food-Drink-Forecast-7086732/ webcite]
• [58]Montague-Jones G: Martek signs omega-3,-6 supply deal with Fonterra. Dairy Reporter.com 2009. [http://www.dairyreporter.com/Financial/Martek-signs-omega-3-6-supply-deal-with-Fonterra webcite]